Next-generation sequencing for malignant hyperthermia susceptibility offers new opportunities for perioperative risk assessment, though challenges like incomplete penetrance and cost remain.
Malignant hyperthermia (MH) is a rare pharmacogenetic disorder triggered by volatile anesthetics and succinylcholine, most often linked to pathogenic variants in RYR1, CACNA1S, and STAC3. The advent of next-generation sequencing (NGS) has transformed MH diagnostics, offering new opportunities for perioperative risk assessment as caffeine-halothane contracture testing declines. However, challenges remain, including incomplete penetrance, variable pathogenicity of variants, limited access to functional confirmatory testing, and cost. Genetic testing also raises important questions. What is the clinical utility of finding a variant of unknown significance? What are the broader implications of MH susceptibility beyond the operating room? Emerging evidence connects MH susceptibility loci to exertional heat illness (EHI), exertional rhabdomyolysis (ERM), and heat-related mortality, highlighting the need for a broader framework for genetic risk assessment. This review synthesizes historical advances, current consensus, and future directions concerning MH to guide anesthesiologists and perioperative clinicians in leveraging molecular diagnostics for personalized care and improved patient safety.
Saha et al. (Wed,) conducted a review in Malignant hyperthermia susceptibility. Genetic testing (next-generation sequencing) was evaluated. Next-generation sequencing for malignant hyperthermia susceptibility offers new opportunities for perioperative risk assessment, though challenges like incomplete penetrance and cost remain.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: